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ABSTRACT 
 
 
Background and Aim: MRP4/ABCC4 is an ABC transporter that can efflux the 
second-messenger, cAMP, from cells. MRP4 has a PDZ-interacting motif at its carboxy 
terminal end through which it binds to scaffolding proteins NHERF1 and PDZK1. 
Previous studies have shown that PDZK1 serves as a scaffold physically coupling MRP4 
with the cystic fibrosis transmembrane conductance regulator (CFTR). This protein 
complex functionally couples cAMP regulation of CFTR function with MRP4 cAMP 
transporter activity [Li, C., et al., Spatiotemporal coupling of cAMP transporter to CFTR 
chloride channel function in the gut epithelia. Cell, 2007. 131(5): p. 940-51]. We 
hypothesized that the MRP4 PDZ domain can bind MRP4 to scaffolding proteins other 
than NHERF1 and PDZK1 and that those PDZ proteins serve to physically and 
functionally link MRP4 to other proteins involved in cAMP signaling. High expression of 
MRP4 has been observed in normal prostate and in human prostate cancer cell lines such 
as LNCaP cells [Cai, C., et al., Androgen induces expression of the multidrug resistance 
protein gene MRP4 in prostate cancer cells. Prostate Cancer Prostatic Dis, 2007. 10(1): 
p. 39-45]. In these cells, there are reports that the β2 adrenergic receptor (β2AR), a G 
protein-coupled receptor that ultimately signals through cAMP, is also highly expressed 
[Kasbohm, E.A., et al., Androgen receptor activation by G(s) signaling in prostate cancer 
cells. J Biol Chem, 2005. 280(12): p. 11583-9]. β2AR also has a PDZ-interacting motif at 
its carboxy terminal end. We hypothesized that in these cells there is the possibility of 
interaction between MRP4 and β2AR through a shared PDZ protein, leading to physical 
and functional association of these proteins.  
 
Methodology: We probed Panomics PDZ protein arrays with biotinylated MRP4 
peptides consisting of MRP4 PDZ interacting motif, and identified potential PDZ partner 
proteins to which MRP4 peptide binds. We used LNCaP cells to quantify the mRNA 
expression of these putative PDZ partner proteins, as well as MRP4 and β2AR. We 
carried out pull down assays to test for physical association between the three proteins. 
We used a cAMP reporter assay to test whether activation of β2AR induced cAMP 
signaling and determine whether this signaling was modulated by MRP4 inhibition. 
 
 Results: Out of 93 PDZ domains, MRP4 showed interaction with 24 PDZ 
domains. The five candidate PDZ proteins chosen for further studies met the following 
criteria: (a) They were documented in the literature to interact functionally with GPCRs 
(G protein-coupled receptors) that upon stimulation couple with Gα proteins and cause a 
rise in intracellular cAMP, and (b) They were expressed in prostate cells and co-localized 
with MRP4. Based on previous studies, only two PDZ domains, NHERF1 and MAGI3, 
were reported to bind with Gαs, which is a subunit responsible for production of cAMP 
in response to activation of certain types of GPCRs. LNCaP cells have higher expression 
of MRP4 and β2AR (a G protein-coupled receptor that binds Gαs subunit). Using pull 
down assays, we showed a physical association between MRP4 and β2AR. We also 
showed a functional association between β2AR and MRP4, because inhibition of MRP4 
modulated β 2 AR-induced cAMP signaling in LNCaP cells.  
 
 vi 
Conclusion: MRP4 is physically and functionally associated with the β2AR in 
LNCaP cells. This association may be facilitated by a scaffolding protein, which may be 
MAGI3. This protein may be responsible for holding the macromolecular complex of two 
proteins, MRP4 and β2AR. This association may be important for regulating cAMP 
levels in LNCaP cells and affecting the downstream expression of certain genes that 
depend on the cAMP signal transduction. 
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CHAPTER 1.    INTRODUCTION 
 
 
MRP4/ABCC4 
 
Drug transporters play an essential role in absorption, distribution and excretion 
of drugs. Drug transporters are broadly classified as uptake and efflux transporters. 
Uptake transporters are those that transport drugs into cells, and efflux transporters are 
those that efflux drugs out of cells. Multi drug resistance protein 4 or MRP4/ABCC4 is 
an efflux transporter that belongs to C subfamily of ABC transporters.  
 
Though MRP4 was discovered as a homologue of MRP1 [3] in 1997, its valuable 
function as an efflux transporter of antiviral drugs [4] was discovered a couple of years 
later. Subsequent research on this transporter also revealed that MRP4 substrates are 
endogenous compounds, such as cAMP [5]. Some of the ABCC transporters (e.g., MRP2, 
CFTR and MRP4) have a unique feature of having a PDZ domain at their carboxy 
terminal end─a domain that aids in protein-protein interactions. This PDZ domain allows 
the transporter to bind to PDZ proteins. The PDZ proteins can bind multiple proteins with 
PDZ domains, and thus they function as a scaffold to facilitate physical interactions 
between these ABC transporters with other transporters, receptors and ion channels, 
leading to involvement in and subsequently effecting different signaling pathways. 
Before exploring the wide range of MRP4 substrates, let us look at the gene structure, 
protein expression patterns and localization of MRP4 along with different domains that 
are present in the protein. 
 
 
MPR4 Gene 
 
MRP4 gene is a highly polymorphic gene [6] that consists of 31 exons and 30 
introns. There are multiple MRP4 alternative mRNAs. Alternative splicing of alternative 
exons 1a and exon 1b singly and in combination can occur. In some transcripts the 
presence of these alternative exons leads to formation of premature termination codons 
and the mRNA transcripts undergoes nonsense mediated decay. This mechanism may act 
as a regulator for expression of transcripts of MRP4 in a particular cellular environment, 
which subsequently may control the expression of functional MRP4 protein [7]. While 
MRP4 is ubiquitously expressed, localization of MRP4 is unique when compared to more 
restricted cellular/tissue localization of MRP2 or CFTR [8, 9]. In addition, while MRP2 
and CFTR are apically expressed, MRP4 in some tissues is apically localized and in other 
tissues is basally localized [5]. 
 
 
MPR4 Localization 
 
MRP4 is basolaterally localized in tissues like prostate, liver and brain choroid 
plexus. Higher expression of MRP4 has been observed in prostate [10] and it is localized 
at the basolateral membrane of tubuloacinar cells[5]. The expression pattern of MRP4 is 
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observed to be different between normal and prostate cancer cells. In prostate cancer cell 
lines and also in prostate cancer patient samples, higher expression of MRP4 has been 
reported [1, 11]. But gene expression analysis of prostate cancer tissues taken from 
benign and malignant tumors has shown an opposite trend─lower expression of MRP4 
mRNA in malignant tumors [12]. This difference in expression pattern of MRP4 in 
patient samples and cell lines has not yet been noticed or addressed. In liver, MRP4 is 
localized on the basolateral membrane (sinusoidal side). Loss of MRP4 (MRP4 
knockdown mice) in obstructive cholestatsis leads to tissue damage, which may not be 
compensated by the change in expression of other transporters to protect liver from the 
cholestatic injury. This shows that induced MRP4 expression in cholestatsis protects liver 
from excessive bile acid accumulation [13].  
 
Dual localization of MRP4 has been observed in brain and human colonic 
epithelial cells. In brain choroid plexus epithelium, MRP4 is localized to the basolateral 
membrane of choroid plexus epithelium, and apically localized in brain capillary 
endothelial cells. This dual localization of MRP4 aids in protection of brain. However, in 
CNS disease conditions, the dual localization may prevent the entry of drugs into the 
brain. This entry issue may be bypassed by using specific MRP4 inhibitors [14]. Dual 
localization is also observed in colonic epithelial cells, but in these cells higher 
expression of MRP4 is observed at the apical side of the cells [15]. In kidney proximal 
tubules, MRP4 is expressed on the apical membrane of the cells, and this localization 
helps in efflux of substrates of MRP4 into urine[16].  
 
 
MPR4 Substrates 
 
 Large numbers of substrates are effluxes by MRP4 and can be broadly classified 
as drugs or endogenous compounds. Some of these substances can act as MRP4 
inhibitors. Drugs that are effluxed by MRP4 include antiviral drugs like AZT, PMEA, 
Adefovir  and Tenofovir and also anticancer drugs like Methotrexate and Topotecan. 
MRP4 inhibitors include MK571, probenecid, sildenafil and dipyridamole. There are a 
large number of endogenous compounds that are also substrates of MRP4, including 
cAMP, cGMP, bile acids, PGE1 and PGE2 [5]. Many observations show that MRP4 is 
one of the major regulators of intracellular cAMP levels. cAMP is a second messenger 
that is mainly produced by the activation of G Protein coupled receptors. This activation 
of GPCRs receptors stimulates adenyl cyclase, ultimately leading to cAMP production. 
 
As mentioned above, cAMP is a second messenger, is involved in several 
signaling pathways. It has been observed that cAMP is involved in cell growth, 
differentiation and gene expression[17]. cAMP can activate apoptosis or cell growth, and 
that decision can depend on the cell type [18, 19]. It is important to control cellular 
cAMP levels. Low or high cAMP levels lead to different diseases or cytotoxicity[15]. 
Elevated levels of cAMP have been observed in prostate carcinogenesis[20]. Intracellular 
cAMP levels are generally regulated by two mechanisms─hydrolysis by 
phosphodiesterases[21] and ATP-dependent efflux [22].  
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In human colonic cancer epithelial cells, it has been observed that MRP4 controls 
the localized cAMP levels, compartmentalizing cAMP into “cAMP microdomains” [1]. 
In the same cells, it has also been observed that MRP4 interacts with CFTR. This 
interaction is possible because of the physical binding of both CFTR and MRP4 to a 
scaffolding protein, PDZK1. Both CFTR and MRP4 bind to PDZK1 through their PDZ 
interaction domain [15]. MRP4 protein consists of two membrane spanning domains and 
two nucleotide binding domains. These domains are a signature of ABC transporters. 
MRP4 C terminal consists of a PDZ interacting motif or a protein-protein interaction 
domain. Through this domain, MRP4 can bind to PDZ domain proteins called scaffolding 
proteins. As mentioned above, this binding with scaffolding proteins aids MRP4 in 
interacting with other proteins that also bind to scaffolding proteins through their PDZ 
interacting motif. 
 
 
PDZ Proteins/Scaffolding Proteins 
 
 Cells maintain homeostasis of signaling, which is the process of relaying the 
message or stimuli they receive from extracellular molecules to intracellular molecules 
and subsequently affecting the downstream targets of these signaling through protein-
protein interactions. Protein-protein interactions play a central role in maintaining the 
balance in various signaling pathways. In mammalian cells, there are a large number of 
protein molecules involved in cellular signaling [22]. Though we know that through 
protein-protein interactions cells maintain signaling homeostasis, it is surprising that cells 
control these interactions by having the right proteins interact at the right time and at the 
right place without forming wrong networks in the communications [23]. Cells achieve 
this spatio-temporal regulation of proteins by arranging them in complexes and by 
anchoring some of them to the plasma membrane and arranging others in sub-cellular 
locations [24]. 
 
In organizing these protein-protein interactions, some proteins acts as bridges and 
connect with other proteins by bringing them together into a complex. These proteins are 
called adapter proteins or scaffolding proteins. Adapter proteins are the proteins that aid 
in forming the complex between two other proteins. If there are more than two proteins in 
the complex, then the bridging protein is called the scaffolding protein. Both adapters and 
scaffolding proteins may anchor the interacting proteins to the membrane [25]. 
 
 
Scaffolding Proteins Classification 
 
 Scaffolding proteins consist of many protein-protein interaction domains; quite 
commonly they have multiple PDZ domains. Initially these domains were observed as 
sequence repeats in proteins in which they are present and were named GLGF domains. 
The acronym PDZ was coined based on the first letter present in each protein, i.e., P 
(from PSD 95/SAP 90, Post Synaptic Density 95), D from (DLG, Disc Large Protein) 
and Z from (ZO1, Zonula Occludens) [26]. PDZ domains can be classified into two  
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types ─ simple/complex scaffolding proteins and family based proteins. Simple 
scaffolding proteins are those proteins that only have PDZ domains, e.g., PDZK1 and 
PDZK2. Complex scaffolding proteins are those proteins that have other protein 
interaction domains along with PDZ domains, e.g., NHERF1, MAGI3 and MUPP1, etc. 
[27]. Family-based proteins are classified based on a family. For example, family of PDZ 
proteins with only PDZ domains, MAGUK family proteins, or proteins additionally 
having other protein domains along with PDZ domains [24, 28].  
 
Scaffolding proteins are classified based on families, and one such family is 
MAGUK. Proteins in this family have approximately six PDZ domains and these proteins 
may play a role in tumor suppression and cell surface expression of interacting proteins. 
MAGUK family has been classified into subfamilies, one subfamilies being 
MAGI─Membrane-associated guanylate kinase inverted orientation. MAGI3 belongs to 
the MAGI family. MAGI 1 and 2 are scaffolding proteins, each having a specific 
expression pattern. MAGI 1 and 3 are widely expressed. MAGI1 is highly expressed in 
brain and MAGI2 also has neuronal expression [29]. MAGI3 is a tight junction protein 
with six PDZ domains, two WW domains and one GUK domain [30]. Localization of 
MAGI3 has been observed both in nucleus and tight junctions in different cellular 
environments [31]. MAGI3 PDZ domain has shown binding with TGFα [32], Frizzle, 
Ltap [33]], receptor tyrosine kinase [34] and β1AR [31]. PDZ domain 3 MAGI3 binds 
PTEN [35]. PDZ domain 5 interacts with LPA2 and BAI-1 [[30]. NMDA receptor binds 
to PDZ domain 6 of MAGI3 [31]. 
 
PDZ domains are 80-90 amino acid length sequences and can bind to the carboxy 
terminal of PDZ domain interacting motifs of interacting proteins or to the internal motifs 
of interacting proteins. PDZ domains can homodimerize with other PDZ domains in the 
same protein or heterodimerize with PDZ domains of other PDZ proteins and can also 
interact with lipids [36]. Interaction or binding of the PDZ domain with carboxy terminal 
PDZ domain interacting motifs may be a simple tethering when they are in proximity or 
through an allosteric regulation [37]. PDZ domain interacting motifs are broadly 
classified into four classes (with some exceptions). This classification is based on the 
interaction of their last three amino acids (0,-1 and -2) with PDZ domains [38, 39].  
 
Class I PDZ motifs are the ones that have a pattern of “X-T/S-X-Φ/” where X is 
any amino acid at -3 position, T/S (T is threonine, S is serine) at -2 position, X is any 
amino acid at -1 position and Φ/ (Φ is hydrophobic,  is aromatic) at position 0 mostly. 
In class I PDZ motis, at 0 position there would be V/L (V is valine, L is leucine). Some of 
the transporters either in SLC or ABC come under the class I PDZ motifs. Proteins with 
class I PDZ motifs include MRP2, CFTR, MRP4, OAT4, OCTN1, OCTN2 and Β2AR 
[26, 27, 38]. Class II PDZ motifs have the following pattern of amino acids at their 
carboxy terminal “X- Φ/ -X- Φ/,” which is any amino acid at -3 position, 
hydrophobic or aromatic amino acid at -2 position, any amino acid at -1 position and 
hydrophobic/ aromatic amino acid 0 position. Proteins having class II PDZ domains are 
Neurexin, Syndecan and dopamine transporter (DAT) [26, 38, 40]. Class III PDZ motifs 
have the pattern of “G/E-D/E-X- Φ/” amino acids at their carboxy terminal end. Class 
III motifs have G/E (G is glycine, E is glutamic acid) amino acid at their -3 position, D/E 
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at -2 position (D is aspartic acid, E is glutamic acid), any amino acid at -1 position and a 
hydrophobic/aromatic amino acid at 0 position. Proteins having class III PDZ motifs are 
melatonin receptor, KIF17, myotilin and FATZ.[26, 38]. Class IV proteins have the 
pattern of “X-X--D/E/,” which is any amino acid at -3 and -2 positions, aromatic 
amino acid at -1 position and D/E/ at 0 position ( any amino acid other than Φ/). 
Computationally, class IV motif has been observed in some ion channels and viral 
proteins, but in vivo analysis does not yet confirm the in vitro or computational findings 
[38, 39].  
 
 
Function and Association 
 
 Interaction of proteins having PDZ domain interacting motifs with proteins 
having PDZ domains results in the formation of a protein-protein complex, as mentioned 
above. This complex formation may result in physical and/or functional interaction of 
proteins. This interaction may even aid in cell surface expression of the interacting 
proteins and may also affect different signal transduction pathways in which these 
interacting proteins are involved [27]. Our interest is in interactions between transporters 
and their interacting partners, like ion channels, receptors and other transporters, etc. 
These interactions may affect the drug metabolism or disposition, or it may affect the 
transport of endogenous compounds, subsequently affecting signal transduction 
associated with it.  
 
Functional association of PDZK1, a scaffolding protein, has been observed with 
transporters like OCTN1, OCTN2, URAT1, PEPT1 and PEPT2. A profound effect of the 
association of PDZK1 was observed upon its interaction with OCTN2. When PDZK1 is 
cotransfected with OCTN2, a 6-fold increase in carnitine transport by OCTN2 has been 
observed. An increase in transport was also observed with OCTN1, URAT1 and PEPT1 
when these respective transporters are cotransfected with PDZK1 [38, 41-45].  
 
Physical association of scaffolding proteins with transporters may bring different 
transporters or receptors near to each other, leading to indirect physical association and 
direct functional association of interacting transporters or transporters with receptors. 
PEPT1/ PEPT2 and NHE3 transporters and scaffolding proteins PDZK1 and NHERF1 
are co-expressed primarily on the apical membrane of cells [46, 47]. Uptake of substrates 
by both PEPT1/PEPT2 depends on an H+ gradient as NHE3 is expressed on the same 
membrane and has been proven as the supplier of H+ gradient [48, 49]. As the scaffolding 
proteins are expressed on the same membrane of the cells and can interact with the 
above-mentioned transporters, the functional association of NHE3 with PEPT1/PEPT2 
may be aided by the physical association of transporters to different domains of same 
scaffolding proteins PDZK1 or NHERF1. It may be also possible that these transporters 
may bind to either of the scaffolding proteins and these scaffolding proteins may 
heterodimerize and bring the transporters into the vicinity of each other [27, 48]. 
 
Along with functional and physical association of proteins with PDZ motifs, PDZ 
domain proteins regulate or aid cell surface expression of interacting proteins [27]. 
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Membrane proteins are anchored to the membrane and internalized into cells for 
degradation or recycled back to the cell surface. Transporters having PDZ motifs are 
mostly anchored to the apical membranes in polarized cells. PDZ motifs may play a role 
in the sorting of transporters to the membrane along with other signals that are required 
for membrane anchoring [27, 50, 51]. Membrane sorting of transporters like MRP2, 
CFTR and MRP4 in some cell types is based on the interaction between the PDZ motif 
and PDZ domains of scaffolding proteins [27, 47, 51, 52]. Along with sorting, scaffolding 
proteins also regulate the stability of the interacting proteins/transporters; this 
stabilization leads to an increase in the transport activity of the transporters, which has 
been observed when transporters and scaffolding proteins are cotransfected. An opposite 
effect was observed with mutation of the PDZ motifs/ PDZ domains or transfecting 
transporters alone [42, 49, 53, 54]. One way of increasing stability would be controlling 
or reducing internalization of membrane proteins. CFTR interacts with NHERF1 and as 
NHERF1 interacts with actin through its ERM domain, this interaction may reduce the 
internalization of CFTR by preventing endocytosis [55].  
 
Thus scaffolding proteins also control the stability and cell surface expression of 
interacting proteins/transporters by regulating internalization or recycling of interacting 
proteins [56, 57]. CFTR recycling frequency was decreased when its PDZ motif was 
deleted, leading to a decrease in its half-life at the membrane [57]. Knock down of 
NHERF1 resulted in a change in the frequency of recycling of MRP2, leading to a 
decrease of MRP2 protein at the membrane [58]. On the other hand, when interaction 
between NHERF1 and MRP4 is disrupted, a decrease in internalization of MRP4 with 
increasing amounts of MRP4 at the membrane has been observed. This may be due to a 
decrease in recycling [59]. Internalization and recycling regulates signal transduction 
along with cell surface expression and stability when the interactions involved are either 
receptors/transporters with scaffolding proteins. Beta2 adrenergic receptor recycling is 
affected by the breaking of its binding with NHERF1 [60]. 
 
Signal transduction pathways are also regulated by the interaction of scaffolding 
proteins with proteins having PDZ motifs This may be due to the effect of these 
interactions on functional and physical association or cell surface expression, or on 
stability as mentioned above. CFTR and MRP4 are physically and functionally associated 
through PDZK1, and this association of the two transporters leads to compartmentalized 
regulation of signal transduction of cAMP required for the function of CFTR [36]. Also, 
β2AR and CFTR are physically and functionally associated through NHERF1, and this 
association allows compartmentalized regulation of CFTR channel function through the 
β2 receptor. As β2AR regulates cAMP levels, and cAMP is essential for regulating CFTR 
mediated chloride secretion, the macromolecular complex between the receptor and the 
transporter maintains homeostasis of signal transduction mediated by the receptor and the 
the transporter [61]. 
 
MRP4 is an efflux transporter of cAMP, and G protein coupled receptors are one 
of the upstream regulators of cAMP. Both the MRP4 transporter and GPCRs have class I 
PDZ motifs at their carboxy terminal ends. GPCRs are involved in numerous signaling 
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pathways, and their function is also regulated by scaffolding proteins because these 
receptors interact with scaffolding proteins through their PDZ motif. 
 
 
GPCRs 
 
 G Protein coupled receptors belong to the family of seven transmembrane 
spanning proteins. GPCRs are membrane-bound receptors whose localization and 
internalization and signaling are mediated through protein-protein interactions. GPCRs’ 
activation by an agonist leads to activation of heterotrimeric G protein subunits α, β and 
γ. In other words, activation of GPCRs leads to dissociation of the complex of α, β and γ 
into Gα and Gβγ subunits. These subunits can activate or inhibit the downstream substrates 
or effectors. Gα subunit can be classified or referred to as four different subunits: Gαs 
activates adenylyl cyclase, Gαi inhibits adenylyl cyclase and activates GIRK, Gα12/13 
activates Rho GEFs and Gαq activates phospholipase [62-64]. 
 
 
Classification of GPCRs 
 
 Beta adrenergic receptors mostly couple with Gαs and activate adenylyl cyclase. 
These receptors belong to the family of GPCRs. There are three subtypes of beta 
adrenergic receptors: Beta 1 is highly expressed in heart and brain, beta 2 is ubiquitously 
expressed and beta 3 is expressed in adipose tissue. Beta 2 and 3 adrenergic receptors are 
also capable of coupling Gαi in certain cell types or tissues. All three receptors share a 
homology of approximately 50%. When these receptors couple with Gαs after stimulation 
with an agonist, Gαs activates adenylyl cyclase, leading to generation of cAMP. This 
generated cAMP activates PKA [36, 65]─following which, GPCRs β1 and β2AR couple 
with Gαs,  
 
Although there is high sequence similarity between beta 1 and 2 adrenergic 
receptors, each receptor has a unique expression pattern. In certain cell types both 
receptors are co-expressed. However, after activation by agonists, which leads to increase 
in similar cAMP levels, they have different effects on the downstream effectors. Both 
receptors have class I PDZ domain at their carboxy terminal end, but they bind to 
different scaffolding proteins. One of the reasons for this behavior may be due to the 
difference in expression patterns of scaffolding proteins [31, 65]. 
 
 
GPCRs Coupling with Gαs 
 
 β1AR, through its PDZ interacting motif, binds to different scaffolding proteins 
which effect the receptors’ localization and signal transduction. Interaction of β1AR with 
CAL prevents it from recycling to the plasma membrane, and interaction of MAGI2 with 
β1AR promotes receptor internalization. But the interaction of β1AR with PSD-95 
inhibits receptor internalization [66-68]. As mentioned above, interaction of β1AR with 
scaffolding proteins affects the signal transduction pathways. β1AR binds with its PDZ 
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interacting motif to the scaffolding protein CNrasGEF. When β1AR is activated by an 
agonist like isoproterenol, it leads to the dissociation of Gαs from the heterotrimeric 
complex, thus activating adenylyl cyclase and subsequently increasing cAMP levels in 
the cells. This cAMP binds to the catalytic domain of CNrasGEF, leading to the 
activation of Ras. This interaction of β1AR shows a direct relation between its signal 
transduction pathways and scaffolding protein interaction [69]. 
 
β1AR interaction with scaffolding proteins like GIPC and MAGI3 decreases 
ERK1/2 activation which is mediated through Gαi.. It has been reported that coexpression 
of β1AR and MAGI3 led to greater membrane localization of MAGI3, and this 
localization may enhance the interaction between β1AR and other membrane proteins. 
Both GIPC and MAGI3 have no effect on the amount of cAMP generated and 
internalization of β1AR, showing that some of the interactions with scaffolding proteins 
affect a part of signal transduction pathways instead of affecting the whole signal 
transduction pathways. β1AR and MAGI3 interaction was observed in various tissues 
like heart, brain and kidney [31, 70] 
 
As mentioned earlier, β2AR also has class I PDZ domain similar to β1AR, but 
each of these receptors interact with different PDZ proteins. The “DSLL” domain of 
β2AR is not conserved among other adrenergic receptors, and this may be one of the 
reasons for specific interactions of subtypes of adrenergic receptors, along with 
differential expression of scaffolding proteins [31, 65]. β2AR couples with both Gαs and 
Gαi proteins [71]. Agonist-stimulated β2AR interacts with NHERF1 and regulates NHE 
activity or, in other words, association of β2AR and NHERF1 activates NHE activity 
when β2AR is activated. But mutation in the PDZ motif of β2AR leads to the inhibition 
of NHE3 activity; this shows that association of β2AR with NHERF1 is required for 
regulation of NHE3 [65, 72-74]. β2AR sorting back to the membrane is also associated 
with its binding with NHERF1 [60]. β2AR and NHERF1 association also regulates 
PDGFR ERK signaling. This regulation is possible because both β2AR and PDGFR can 
bind to NHERF1 through PDZ interacting motifs [65, 75]. 
 
β2AR associates with P2Y1 receptor through its interaction with NHERF2 [76]. 
β2AR peptide interacts with NHERF 1 and 2 and PDZK1 scaffolding proteins that were 
overlaid on a protein array. β1AR peptide was also used to probe these scaffolding 
proteins but the peptide interaction was with completely different scaffolding proteins. 
When the last amino acid of β1AR, Valine, was changed to Leucine (or “ESKV” to 
“ESKL”), then the interactions were observed with NHERF 1 and 2 and PDZK1, an 
interaction which is similar to that of the β2AR peptide [31]. Both β2AR and β1AR bind 
to a scaffolding protein MAGI3, but they bind to different PDZ domains of the 
scaffolding protein. β2AR binds to 5th PDZ domain of MAGI3 and β1AR binds to 1st. 
PDZ domain of MAGI3. One more difference is the following: Binding of β2AR and 
MAGI3 is agonist stimulated, but β1AR and MAGI3 binding is constitutive. ERK 1/2 
signaling is decreased when either of the receptors binds to MAGI3 [31, 77]. 
 
In this study, we observed that a MRP4 peptide containing its PDZ-interacting 
motif bound to several scaffolding proteins, included previously published interactions 
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with NHERF1 and PDZK1. We report an interaction between MRP4, a cAMP efflux 
transporter, and β2AR, an upstream regulator of cAMP signaling, which is likely 
happening through a novel scaffolding protein, MAGI3.  
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CHAPTER 2.    MATERIALS AND METHODS 
 
 
 To find the expression and also interaction, if any, between MRP4, β2AR and 
MAGI3 we used LNCaP cells. Below the different materials and methods that were used 
and applied to identify the expression and interaction between the three proteins are 
discussed. 
 
 
Materials 
 
 
Antibodies 
 
MRP4 rat monoclonal antibody (M4I-10) its use has been described in the 
literature [14]. Sheep polyclonal antibody was raised against MAGI3 (PA1-12324, Pierce 
Antibodies, Rockford, IL, USA). Goat polyclonal antibody was raised against β2AR and 
Rabbit polyclonal antibody was raised against β2AR (ab40834 and ab36956, 
respectively, Abcam, Cambridge, MA, USA). Mouse monoclonal antibody was raised 
against NHERF1 (ALX-804-438, Enzo Life Sciences, Farmingdale, NY, USA).  
 
 
Chemicals 
 
Isoproterenol Hydrochloride (I6504, Sigma-Aldrich, St. Louis, MO) and MK571 
(70720, Cayman Chemical, Ann Arbor, MI) are the chemicals that are used as β2AR and 
MRP4 agonist and inhibitor, respectively.  
 
 
Plasmids 
  
pCRE-MetLuc2, pMet-Luc2-Control and pSEAP2-Control plasmids (631745, 
631717, Clonetech, Mountain View, CA) are the secreted luciferase transfected in 
LNCaP cells . PDZ arrays II-IV (Panomics TranSignalTM, Panomics, Fremont, CA) are 
the arrays which were probed with MRP4 peptide.  This MRP4 peptides are biotin 
conjugated  containing the carboxy-terminal 7 a.a and 10 a.a (MRP4 C-7, C-10) of 
MRP4. These peptides were synthesized by the Hartwell Center at St. Jude Children’s 
Research Hospital. Transfection reagent used was Fugene HD (04709705001, Roche, 
Mannheim,Germany) 
 
 
Tissue Culture 
 
 LNCaP (human prostate adenocarcinoma) cells were obtained from ATCC 
and were cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin, 1% glutamine and 1% sodium pyruvate. MDCK II cells stably 
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over expressing empty vector or mMAGI3 were kindly provided by Dr. Robert J. Coffey 
(Vanderbilt University Medical Center). LLC-PK1 cells were grown in MEM 199 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Jurkat cells 
were grown in RPMI 1640 supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin and 1% glutamine. Saos2 cells stably expressing hMRP4 or 
empty vector were kindly provided by Dr. John Schuetz and were maintained in DMEM 
with 10% fetal bovine serum, 1% penicillin/streptomycin and 1% glutamine. 
 
 
Methods 
 
 
PDZ Arrays 
 
Arrays consist of GST coupled to PDZ domains of scaffolding proteins 
(Panomics TranSignalTM. PDZ Domain Arrays II-IV). These arrays or membranes were 
incubated in 1x wash buffer for 30 min. Then the membranes were incubated for 2 
hours at room temperature in 5 ml of 1x blocking buffer. 15 µl of the biotin-MRP4 
C7/C10 peptide (200 µM) was mixed with 15 µl of avidin horsedish peroxidase 
(1mg/ml) and incubated for 30 min at 4 oC. The peptide avidin mix was added into 5 ml 
of 1x blocking buffer (final MRP4 C7/C10 peptide concentration 600 nM) and 
incubated with the array for 2 hr at room temperature. After incubation, membranes 
were washed three times in 1x wash buffer and binding of the peptide was detected 
using enhanced chemiluminescence and quantified using Bio-Rad universal hood II. 
 
 
RT-PCR 
 
Total RNA was isolated using TRIzol from LNCaP cells. First-strand cDNA was 
prepared using oligo (dT) primers (ThermoScript RT-PCR system, Invitrogen, Catalog 
number 11146-016). Real-time PCR quantitation of MRP4, β2AR, MAGI3 and GAPDH 
was carried out using the SYBR GreenER qPCR supermix (Invitrogen Catalog number 
11760-100) according to the manufacturer’s instructions. cDNA was analyzed in 
duplicate by quantitative real-time PCR on an ABI PRISM 7900HT Sequence Detection 
System (PE Applied Biosystems, Foster City, CA). Primers used for real-time 
quantification are provided in Table 2.1. The absolute Ct values of MRP4, β2AR and 
MAGI3 were normalized with absolute Ct values of GAPDH to obtain mRNA expression 
levels. 
 
 
CRE (cAMP Response Element) Luciferase Reporter Assay 
 
LNCaP cells grown in RPMI 1640 supplemented with 10% charcoal stripped fetal 
bovine serum, 1% penicillin/streptomycin, 1% glutamine, 1% sodium pyruvate, were 
plated at 2 x 105  in a 24 well plate. After 24 hours, these cells are transfected with either  
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Table 2.1. zPCR primers. 
 
Gene Forward Primer Reverse Primer 
 
MRP4 
 
CAACTCCTCTCCAAGGTGCT 
 
ATCTGCTCACGCGTGTTCTT 
β2AR TCCTGGATCACATGCACAAT GAGCACAAAGCCCTCAAGAC
MAGI3 CACTTGCTGCAGTTTGTGGT GAGCCCATCCGTCTCAAG 
 
 
1 µg pCRE-MetLuc2 or the pMet-Luc2-Control vector and contransfected with 1 µg 
pSEAP2-Control (secreted alkaline phosphatase) plasmid to control for transfection  
efficiency. After 24 hours of transfection, the media was changed with fresh medium 
containing 0.1% DMSO, Isoproterenol (250/500 nM), MK571 (25 µM) and Isoproterenol 
+ MK571 (250/500 nM, 25µM). These plasmids secrete luciferase protein in the media.  
 
After 24 hours of treatment with the above-mentioned chemicals, media was 
collected and substrate was added according to the manufacturer’s protocol. For 
normalization purposes, media was taken and SEAP substrate was added according to the 
manufacturer’s protocol. Both luciferase and SEAP values were read on a luminometer, 
BioTek Synergy H4 hybrid reader, and the luciferase activities are normalized to SEAP 
values. 
 
 
Pull-down Assay, Co-immunoprecipitation and Immunoblotting 
 
LNCaP cells were plated at 1.5 x 106 in 10 cm dishes. After 24 hours of plating, 
media was removed and cells were washed twice with PBS and were scrapped using a 
scrapper in a solution of PBS + protease inhibitors. Cell lysates were collected in an 
eppendorf tube and centrifuged at 1,000 g for 5 min at 4 ˚C. Then the supernatant was 
removed. To the remaining pellet, M-PER + Protease inhibitors (lysis buffer) were added 
and incubated on ice for 30 min. Then the mixture is centrifuged at 14,000 g for 25 min at 
4 ˚C. Then the supernatant was taken and protein concentration of the cell lysates was 
determined by Bradford assay (Pierce, Rockford, IL). In case of isoproterenol treated 
cells, LNCaP Cells were plated at 1.5 x 106 in 10 cm dish. After 24 hr of plating, 
isoproterenol 750 nM was added to the cells and cells were lysed. Lysates (500 µg) of 
LNCaP cells treated or untreated with isoproterenol was placed in tubes and the volume 
adjusted to 200 µl using Ab binding and wash buffer provided by manufacturer. To this 
mixture, β2AR antibody (1:100), MRP4 antibody (1:50) and non-immune IgG were 
added, respectively (1:100 or 1:50), and this mixture was incubated for 20 hr at 4 ˚C with 
constant mixing. After 20 hr, the mixture was incubated with Protein G Dynabeads for 4 
hr at 4 ˚C with constant mixing. Then, 3 washes were done using wash buffer provided by 
Invitrogen, and mild elution was done using elution buffer provided by Invitrogen, and 
then denaturing elution was done using a mixture of M-PER + protease inhibitors with 
laemmli buffer (containing 5% B-Mercaptoethanol). After adding the mixture, the 
denaturing elution was done by heating at 65 ˚C for 10 min. Elutes were separated on 7.5-
10% SDS PAGE. For co-immunoprecpitation and immunoblotting, after separation on 
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PAGE, the gel was transferred to PVDF membranes and immunoblotted using either 
anti-MRP4 or anti-β2AR antibodies (immunoprecipitation or pull down). For 
co-immunoprecipitation, if the pull downwas done by anti-MRP4 antibody, then 
membranes were probed with anti-β2AR and anti-MAGI3 antibodies. After pull down 
using anti-β2AR, antibody membranes were probed with anti-MRP4 and anti-MAGI3 
antibodies. 
 
For immunoblotting of MRP4, β2AR and MAGI3 in LNCaP, Saos2 cells 
expressing hMRP4 and MDCKII cells expressing mMAGI3 were plated at 1.5 x 106 in 10 
cm dish. After 24 hr of plating, media was removed and cells were washed twice with 
PBS and were scrapped using a scrapper in a solution of PBS + protease inhibitors. Cell 
lysates were collected (in case of Jurkat cells, because of being suspension cells, they 
were collected in eppendorf tube and centrifuged  in an eppendorf tubes  at 1,000 g for 5 
min at 4 ˚C. Then supernatant was removed and to the remaining pellet, M-PER+ 
Protease inhibitors (lysis buffer) were added and incubated on ice for 30 min. Then the 
mixture was centrifuged at 14,000 g for 25 min at 4 ˚C. Then supernatantwas taken and 
protein concentration of the cell lysates was determined by Bradford assay (Pierce, 
Rockford, IL). Elutes were separated on 7.5-10% SDS PAGE and immunoblotting was 
performed after separation on PAGE. Gel was transferred to PVDF membranes and 
membranes were probed using anti-MRP4, anti-β2AR and anti-MAGI3 antibodies. 
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CHAPTER 3.    RESULTS 
 
 
 ABCC4/MRP4 PDZ Domain Interactions or MRP4 PDZ Interactome 
 
 MRP4/ABCC4, at its carboxy terminal, has a PDZ domain interacting motif. This 
is a class I motif “TAL” at its -2,-1, 0 positions. Through this motif, MRP4 interacts with 
PDZ domains of PDZ proteins or scaffolding proteins. It has been observed that MRP4 
through its PDZ domain interacting motif interacts with two scaffolding proteins, PDZK1 
and NHERF1 [36, 78].We hypothesized that there may be other scaffolding proteins with 
which MRP4 may interact through its PDZ domain interacting motif. To investigate this 
hypothesis, we used two biotinylated MRP4 peptides (C7 and C10) to probe the 
Panomics protein arrays (II-IV). These arrays have 95 scaffolding proteins. Peptides C7 
and C10 comprise the last seven and ten amino acids of the Carboxy-terminus of the 
MRP4 protein, respectively, with a linker and biotin at its N-terminus. C10 peptide has 
“STL” at its -7,-8,-9 position and resembles Class I PDZ domain interacting motif or an 
internal motif that can interact with PDZ domains of PDZ proteins. We used C7 peptide, 
which lacks “STL” amino acids that are present in the C10 peptide. This would give us 
an idea whether having “STL” or not makes any difference in binding or interaction with 
PDZ domain proteins. There were a number of interactions seen between the MRP4 C7 
peptide and the PDZ proteins (Fig 3.1). Out of the 95 PDZ domains on the arrays (II-IV), 
the MRP4 C7 peptide interacted with 24 PDZ domains (Fig 3.1, Table 3.1). PDZK1 and 
NHERF1 PDZ domains were among the 24 domains that interacted with the MRP4 C7 
peptide. This interaction supports the previously reported interaction of MRP4 protein 
with these PDZ proteins and also suggests that these interactions are not non-specific. 
PDZ domain arrays (II-III) were probed with MRP4 C10 peptide. Interactions that were 
observed were similar to MRP4 C7 peptide interactions, but there were three PDZ 
domains that have not interacted with MRP4 C10 peptide (data not shown). Results 
obtained from MRP4 C7 interaction are presented in Fig 3.1 and Table 3.1.  
 
Because MRP4 is an efflux transporter of cAMP [36], and because receptors 
belonging to family of GPCRS are regulators of cAMP signaling pathways, [63, 79] we 
were interested in pursuing scaffolding proteins that bound with the MRP4 PDZ peptide 
and that further met two criteria:Tthey had to bind with GPCRs involved in cAMP 
signaling, and their expression and localization pattern had to be similar to that of MRP4 
protein expression and localization. As mentioned earlier, these scaffolding proteins aid 
in protein-protein interactions and help different proteins to form a macromolecular 
complex, leading to synchronous operation of signaling pathways. From the 24 PDZ 
domains that interacted with the MRP4 PDZ peptide, we identified 5 that are involved in 
binding with GPCRS, and that co-localized with MRP4 (Table 3.2).  
 
We were interested in testing whether the in vitro MRP4 PDZ interactions 
observed by peptide and array probing could be observed between the full length MRP4 
and scaffolding proteins and which are potential GPCR interacting proteins. We 
purposefully elected not to test for these interactions by transfecting cells with expression  
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Figure 3.1. Interaction of the MRP4 Class I PDZ domain with PDZ domains of 
various scaffolding proteins.  
 
PDZ arrays (Panomics) II-IV (spotted with scaffolding proteins) probed with MRP4 
peptide. (A) MRP4 biotinylated C-tail peptide (last 7 amino acids) (B) MRP4 
biotinylated C-tail peptide (last 10 amino acids). (C,E,G) arrays II – IV probed with C7 
MRP4 peptide; (D,F,H) are a schematic representation of the scaffolding proteins on 
arrays II-IV. Scaffolding proteins in bold are the ones that specifically interacted with the 
MRP4 C7 peptide. 
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Table 3.1. PDZ domains on arrays II, III and IV which bound with MRP4 C7 peptide. 
Position PDZ Domain Protein Name Interaction with MRP4 
Peptide 
Accession  
No. 
Array II     
A1, 2 KIAA0300-D6 KIAA0300 protein, Domain 6  BAA20760 
A3, 4 KIAA0303 KIAA0303 protein  BAA20762 
A5, 6 KIAA0316 KIAA0316 protein +++ BAA20774 
A7, 8 KIAA0559 KIAA0559 protein  BAA25485 
A9, 10 KIAA0613 KIAA0613 protein, Domain 7  BAA31588 
A11, 12 KIAA1719-D7 KIAA1719 protein, Domain 7  BAB21810 
A13, 14 KIAA1719-D4 KIAA1719 protein, Domain 4  BAB21810 
A15, 16 KIAA1719-D3 KIAA1719 protein, Domain 3  BAB21810 
B1, 2 KIAA1526-D3 KIAA1526 protein, Domain 3  BAA96050 
B3, 4 MAST205 Microtubule-associated testis- 
specific serine/threonine 
protein kinase 
+++ BAB40778 
B5, 6 KIAA1849 Hypothetical protein 
KIAA1849 
 BAB47478 
B7, 8 PALS1-D8 Pals1-associated tight junction 
protein, Domain 8 
 AAM28433 
B9, 10 PALS1-D9 Pals1-associated tight junction 
protein, Domain 9 
 AAM28433 
B11, 12 PALS1-D1 Pals1-associated tight junction 
protein, Domain 1 
 AAM28433 
B13, 14 PALS1-D2 Pals1-associated tight junction 
protein, Domain 2 
 AAM28433 
B15, 16 PALS1-D5 Pals1-associated tight junction 
protein, Domain 5 
 AAM28433 
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Table 3.1       (Continued). 
 
   
Position PDZ Domain Protein Name Interaction with 
MRP4 Peptide 
Accession  
No. 
C1, 2 PALS1-D3 Pals1-associated tight junction 
protein, Domain 3 
+ AAM28433 
C3, 4 MGC5395 Similar to hypothetical protein 
MGC5395 
 AAH12477 
C5, 6 FLJ23209-D1 Hypothetical protein 
FLJ23209, Domain 1 
++ NP_079171 
C7, 8 FLJ23209-D2 Hypothetical protein 
FLJ23209, Domain 2 
 NP_079171 
C9, 10 KIAA1719-D6 KIAA1719 protein, Domain 6  BAB21810 
C11, 12 FLJ00011 FLJ00011 protein (fragment) + Q9H7Q6 
C13, 14 E3KARP-D1 Solute carrier family 9, 
sodium/hydrogen exchanger3 
regulatory factor 2, Domain 1 
 NP_004776 
C15, 16 E3KARP-D2 Solute carrier family 9, 
sodium/hydrogen exchanger 3 
regulatory factor 2, Domain 2 
 NP_004776 
D1, 2 NHERF1-D1 Solute carrier family 9, 
sodium/hydrogen exchanger 
Isoform 3 regulatory factor 1, 
Domain 1 
+++ NP_004243 
D3, 4 ZO1-D1 Tight junction protein 1, 
Domain 1 
 Q07157 
D5, 6 ZO1-D2 Tight junction protein 1, 
Domain 2 
 Q07157 
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Table 3.1       (Continued). 
 
Position PDZ Domain Protein Name Interaction with MRP4 
Peptide 
Accession 
No. 
D7, 8 SDB1-D1 Syndecan binding protein  
(syntenin), melanoma 
differentiation associated 
protein-9, Domain 1 
 NP_005616 
D9, 10 SDB1-D2 Syndecan binding protein 
(syntenin),melanoma 
differentiation associated 
protein-9, Domain 2 
 NP_005616 
D11, 12 IL16(2)-D3 Interleukin 16 isoform 2; 
lymphocyte chemoattractant 
factor, Domain 3 
 NP_757366 
D13, 14 LNX1-D3 Numb-binding protein 1; 
Ligand of Numb-protein, 
Domain 3 
 Q8TBB1 
D15,16 NOS1 Nitric oxide synthase 1 
(neuronal), Domain 5 
 NP_000611 
E1, 2 PDZ-pos PDZ Domain positive control 
forKv1.4 ligand 
+++  
E3, 4 GST Glutathione-S Transferase   
 
Array III 
    
A1, 2 MAGI3-D2 Membrane-associated 
guanylate kinase-related 3, 
Domain 2 
+ NP_690864 
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Table 3.1        (Continued). 
 
Position PDZ Domain Protein Name Interaction with MRP4 
Peptide 
Accession 
No. 
A3, 4 MAGI3-D4 Membrane-associated 
guanylate kinase-related 3, 
Domain 4 
 NP_690864 
A5, 6 MAGI3-D5 Membrane-associated 
guanylate kinase-related 3, 
Domain 5 
+++ NP_690864 
A7, 8 MAGI3-D6 Membrane-associated 
guanylate kinase-related 3, 
Domain 6 
+++ NP_690864 
A9, 10 BAI1-D2 Brain-specific angiogenesis 
inhibitor-associated protein 1, 
Domain 2 
+++ NP_004733 
A11, 12 BAI1-D3 Brain-specific angiogenesis 
inhibitor-associated protein 1, 
Domain 3 
+++ NP_004733 
A13, 14 BAI1-D4 Brain-specific angiogenesis 
inhibitor-associated protein 1, 
Domain 4 
 NP_004733 
A15, 16 BAI1-D1 Brain-specific angiogenesis 
inhibitor-associated protein 1, 
Domain 1 
 NP_004733 
B1, 2 BAI1-D6 Brain-specific angiogenesis 
inhibitor-associated protein 1, 
Domain 6 
 NP_004733 
B3, 4 AIP1-D2 Atrophin-1 interacting 
protein 1, Domain 2 
 NP_036433 
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Table 3.1        (Continued). 
 
Position PDZ Domain Protein Name Interaction with MRP4 
Peptide 
Accession 
No. 
B5, 6 AIP1-D3 Atrophin-1 interacting protein 1, 
Domain3 
 NP_036433 
B7, 8 AIP1-D4 Atrophin-1 interacting protein 1, 
Domain 4 
 NP_036433 
B9, 10 AIP1-D5 Atrophin-1 interacting protein 1, 
Domain 5 
+++ NP_036433 
B11, 12 AIP1-D6 Atrophin-1 interacting protein 1, 
Domain 6 
+++ NP_036433 
B13, 14 hPTP1E-D2 Protein tyrosine phosphatase, 
non-receptor type 13 isoform 4, 
Domain 2 
 NP_542416 
B15, 16 hPTP1E-D3 Protein tyrosine phosphatase, 
non-receptor type 13 isoform 4, 
Domain 3 
 NP_542416 
C1, 2 hPTP1E-D4 Protein tyrosine phosphatase, 
non-receptor type 13 isoform 4, 
Domain 4 
 NP_542416 
C3, 4 PTPN4 Protein tyrosine phosphatase, 
non-receptor type 4,  
megakaryocyte phosphatase; 
PTPase-MEG1 
NP_002821 
C5, 6 GRIP1-D4 GRIP1 protein, Domain 4 CAB39895 
 
 
 
 
 21 
Table 3.1        (Continued). 
 
Position PDZ Domain Protein Name Interaction with MRP4 
Peptide 
Accession 
 No. 
C7, 8 GRIP1-D3 GRIP1 protein, Domain 3  CAB39895 
C9, 10 GRIP1-D2 GRIP1 protein, Domain 2  CAB39895 
C11, 12 SCRIB1-D1 Scribble, Domain 1 +++ NP_056171 
C13, 14 SCRIB1-D2 Scribble, Domain 2 +++ NP_056171 
C15, 16 SCRIB1-D4 Scribble, Domain 4 ++ NP_056171 
D1, 2 PARD3-D2 Partitioning-defective 
protein 3 homolog; 
atypical PKC isotype 
isotypespecific 
interacting protein, 
Domain 2 
 NP_062565 
D3, 4 PARD3-D3 Partitioning-defective 
protein 3 homolog; 
atypical PKC isotype 
isotypespecificinteracting 
protein, Domain 2 
 NP_062565 
D5, 6 HARM-D3 Harmonin; PDZ-73 
protein; antigen NY-CO-
38, Domain 3 
 NP_005700 
D7, 8 MLL4 Myeloid/lymphoid or 
mixed-lineage leukemia, 
translocated to 4 
 NP_005927 
D9, 10 
 
TIP1 Tax interaction protein 1  NP_055419 
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Table 3.1        (Continued). 
 
Position PDZ Domain Protein Name Interaction with MRP4 
Peptide 
Accession 
No. 
D11, 12 SDB2-D2 Syntenin-2beta; syntenin-2; 
similar to syndecan binding 
protein, Domain 2 
 NP_056500 
E1, 2 PDZ-pos PDZ Domain positive control 
forKv1.4 ligand 
+++  
E3, 4 GST Glutathione-S Transferase   
     
Array IV     
A1, 2 MUPP1-D6 Multiple PDZ domain protein, 
Domain 6 
 NP_003820 
A3, 4 MUPP1-12 Multiple PDZ domain protein, 
Domain 12 
 NP_003820 
A5, 6 MUPP1-2 Multiple PDZ domain protein, 
Domain 2 
 NP_003820 
A7, 8 MUPP1-3 Multiple PDZ domain protein, 
Domain 3 
+++ NP_003820 
A9, 10 MUPP1-13 Multiple PDZ domain protein, 
Domain 13 
+++ NP_003820 
A11, 12 MUPP1-1 Multiple PDZ domain protein, 
Domain 1 
 NP_003820 
A13, 14 DLG3-D2 Synapse-associated protein 102; 
neuroendocrine-dlg; discs large 
homolog 3, Domain 2 
+++ NP_066943 
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Table 3.1        (Continued). 
 
Position PDZ Domain Protein Name Interaction with MRP4 
Peptide 
Accession 
 No. 
A15, 16 DLG3-D3 Synapse-associated protein 102; 
neuroendocrine-dlg; discs large 
homolog 3, Domain3 
+++ NP_066943 
B1, 2 DLG5-D1 Discs, large homolog 5, Domain 1  NP_004738 
B3, 4 DLG5-D4 Discs, large homolog 5, Domain 4  NP_004738 
B5, 6 DLG5-D3 Discs, large homolog 5, Domain 3  NP_004738 
B7, 8 DLG5-D2 Discs, large homolog 5, Domain 2  NP_004738 
B9, 10 DLG2-D3 Channel associated protein of 
synapse-110 (Chapsyn-110), 
Domain 3 
++ NP_001355 
B11, 12 PAR6B Partitioning defective-6 homolog 
beta Domain 1 
 BAB40756 
B13, 14 LIK1 LIM domain kinase 1 isoform 1; 
LIM motif-containing protein 
kinase 
 NP_002305 
B15, 16 LOMP LIM domain only 7 isoform 
a;KIAA0858 protein 
 NP_005349 
C1, 2 RIL LIM protein RIL (Reversion-
induced LIM protein) 
 NP_003678 
C3, 4 A2LIM Alpha-actinin-2-associated LIM 
protein;enigma homolog 
 
 
 
 
+ NP_055291 
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C15, 16 GEF12           Rho guanine exchange factor (GEF) +++         NP_056128 
             12 
Table 3.1        (Continued). 
 
   
Position PDZ Domain Protein Name Interaction with MRP4 
Peptide 
Accession 
No. 
C5, 6 TIAM1 T-cell lymphoma invasion and 
metastasis 1 
 NP_003244
C7, 8 LIN7C Lin-7 homolog C +++ NP_060832 
C9, 10 LIN7B Lin-7 homolog B +++ NP_071448 
C11, 12 LIN7A Lin-7 homolog A +++ NP_004655 
C13, 14 GEF11 Rho guanine exchange factor 
(GEF)11 
+++ NP_055599 
D1, 2 PDZK1-D1 PDZ domain containing 1, Domain 1  NP_002605 
D3, 4 PDZK1-D2 PDZ domain containing 1, Domain 2 ++ NP_002605 
D5, 6 SNB1 Beta-1-syntrophin; tax interaction 
protein 43 
+++ NP_066301 
D7, 8 SNA1 Acidic alpha 1 syntrophin; 
dystrophin-associated protein A1 
+++ NP_003089 
D9, 10 SHK1 Somatostatin receptor-interacting 
protein; SH3 and multiple ankyrin 
repeat domains 1 
+++  
D11, 12 MPP6 Membrane protein, palmitoylated 6; 
protein associated with Lin7 2;VELI-
associated MAGUK 1; MAGUK 
protein p55T 
 NP_057531 
D13, 14 PIST Golgi associated and coiled-coil 
motif containing protein 
 NP_065132 
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Table 3.1        (Continued). 
 
Position PDZ Domain Protein Name Interaction with MRP4 
Peptide 
Accession 
No. 
D15, 16 GEF2 Rap guanine nucleotide exchange 
factor; PDZ domain-containing 
guanine nucleotide exchange 
factor I 
 NP_057424 
E1, 2 RIM2 Regulating synaptic membrane 
exocytosis 2; RAB3 interacting 
protein 3; KIAA0751 protein 3; 
KIAA0751 protein 
 NP_055492 
E3, 4 PDZ-pos PDZ Domain positive control for 
Kv1.4 ligand 
+++  
E5, 6 GST Glutathione-S Transferase   
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Table 3.2.  Potential PDZ proteins that interact with GPCRS which bound to MRP4 C7 peptide. 
 
S. 
No. 
Protein  
Name 
Domains  
on Array 
Domains 
Interacting 
with 
MRP4 
peptide 
Reported 
Interaction with 
Receptors 
Interacting 
G Proteins 
Intensity     
of  Inter-
action 
Ref 
1 NHERF1 D1 D1 β1AR and β2AR Gαs and Gαi +++ [70,72] 
2 MAGI3 D2,4,5,6 D2,5,6 β1AR , β2AR and LPA2 
Gαs , Gαi 
and Gαq 
+,+++, 
+++ [70,72,100] 
3 MUPP1 D1,2,3,6,12,13 D3,13 Mt1, 5-HT2CR 
Gαi and 
Gαq +++, +++ [80-82] 
4 GEF12   LPA 1 and 2 Gα12/13 +++ [85-87] 
5 SNA1   α1D-AR Gαq +++ [83-84] 
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plasmids since this can create an artificial balance of proteins can drive artificial 
interactions. We tested instead for interactions between endogenously expressed proteins. 
 
We were in search of a cell line where there is expression of MRP4 and β2AR 
(which belong to the family of GPCR and also have a class I PDZ domain interacting 
motif as MRP4). LNCaP cells met above criteria: These cells have higher expression of 
MRP4 [80, 81] and β2AR [62]. MAGI3 appeared to be a potential scaffolding protein 
(out of the five proteins); we have observed interaction between MRP4 and MAGI 3 on 
array. A physical interaction has been reported earlier between β2AR and MAGI3 [82]. 
Even though there were no reports about MAGI3 expression in LNCaP cells, we 
hypothesized that MAGI3 may be expressed in these cells, and MRP4 and β2ARare in 
complex may be through scaffolding protein MAGI3. The next aspect we wanted to 
explore was the expression of these three proteins in LNCaP cells. 
 
 
MRP4, β2AR and MAGI3 are Co-Expressed in LNCaP Cells 
 
MRP4 and β2AR are expressed in LNCaP cells [62, 80, 81], and our results, 
which were obtained from RT-PCR and western blotting, showing mRNA and protein 
expression, respectively (Fig 3.2A, B), supported the published literature. We also 
observed mRNA expression of MUPP1 and protein expression of NHERF1 scaffolding 
proteins in LNCaP cells (data not shown). MAGI3 mRNA and protein expression was 
observed in LNCaP cells (Fig 3.2A, C). Expression of MRP4, β2AR and MAGI3 mRNA 
was higher in LNCaP cells, compared to their expression in HT29-CL19A and Caco2 cell 
lines (data not shown). These expression results showed that all three proteins are 
expressed in this cell line. The next aspect we wanted to explore was whether there is any 
protein-protein interaction between these proteins. 
 
 
ABCC4/MRP4 Interacts with β2AR in LNCaP Cells 
 
In our protein array experiment, MPR4 peptide (having the PDZ domain 
interacting motif) showed interaction with MAGI3 PDZ domains. It has already been 
shown that there is an interaction between MAGI3 and β2AR [82]. We hypothesized that 
MRP4 may interact with β2AR probably through MAGI3, a scaffolding protein in 
LNCaP cells. If all the three proteins are in macro molecular complex, then it would be 
possible to observe interaction between them by immunoprecipitation of one protein and 
co-immunoprecipitation of others. Immunoprecipitation of β2AR from LNCaP cells that 
were treated or untreated with isoproterenol is shown in Fig 3.3A. These results show 
pull down of ß2 AR using the ß2 AR antibody. Immunoblotting of the ß2 AR pulled 
down eluate with anti-MRP4 and anti-MAGI3 antibodies, which showed that MRP4 was 
co-immunoprecipitated and that MAGI3 might also have been co-precipiated. Next, 
MRP4 was immunoprecipitated from LNCaP cells using MRP4 antibody (cells were 
treated or untreated with isoproterenol) (Fig 3.3B). Immunoblott analysis of the MRP4 
pull down showed that ß2 AR was co immunoprecipitated with MRP4 (Fig 3.3B). We 
were not able  
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Figure 3.2. MRP4, ß2AR and MAGI3 expression in LNCaP cells. 
 
(A) RT-PCR results: MRP4, ß2AR and MAGI3 mRNA expression (normalized by 
GAPDH expression) in LNCaP cells (average of two experiments ± range). (B) 
Immunoblot analysis of MRP4 expression in LNCaP, Jurkat, and Saos2-MRP4 (over 
expressing MRP4) cells. (C) Immunoblot analysis of ß2 AR expression in LNCaP, 
Jurkat, Saos2-MRP4 (over expressing MRP4) cells. (D) Immunoblot analysis of MAGI3 
expression in LNCaP, MDCK II (over expressing MAGI3) and MDCK II (stably 
transfected with pCDNA) cells. 
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Figure 3.3. MRP4 interacts with ß2AR through scaffolding protein MAGI3. 
 
(A) LNCaP cells treated or untreated with Isoproterenol were lysed. These lysates were 
used for immunoprecipitation  with anti ß2AR antibody and then were immunoblotted for 
MRP4 and MAGI3. (B) LNCaP lysates were used for immunoprecipitation with anti 
MRP4 antibody and then were immunoblotted for β2AR and MAGI3. 
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to see clear co-immunoprecipitation of MAGI3 with pull down by the MRP4 antibody 
(not shown). We are not sure why this discrepancy is observed between the pull down of 
ß2AR or MRP4 antibody. As mentioned above, we repeatedly found that MAGI3 was  
co-immunoprecipitated when immunoprecipitation was carried out by ß2AR. In total, the 
results of the immunoprecipitation showed there is definitely a physical association 
between MRP4 and β2AR. This asscociation may be mediated by the scaffolding protein 
MAGI3.  
 
 
Inhibition of MRP4 along with β2AR Activation Modifies cAMP Signaling 
 
Next we tested whether there is any functional association between MRP4 and the 
β2AR. The ß2AR belongs to the family of GPCRs, which interacts with different types of 
G proteins. It has been reported that in LNCaP cells, the ß2AR interacts with Gs proteins. 
Activation of β2AR increases its interaction with Gs proteins, stimulating adenylyl 
cyclase and subsequently increasing cAMP levels [62]. MRP4 is a high affinity cAMP 
transporter, which is also expressed in LNCaP cells as shown in our above results and 
also reported previously [80, 81]. We hypothesized that if LNCaP cells were activated 
with isoproterenol, a β2AR agonist, this would result in an increase in cAMP levels. We 
further hypothesized that if MRP4 efflux of cAMP modified β2AR-induced cAMP 
signaling, then inhibition of MRP4 with a specific inhibitor would further increase the 
isoproteronol-stimulated cAMP signal. We also tested whether simply inhibiting MRP4 
in cells (in the absence of ß2AR activation) would increase endogenous cAMP pools and 
result in increased cAMP signaling. Changes in cAMP levels were examined by using a 
CRE-luc reporter assay system, because cAMP effects transcription of downstream target 
genes through activation of the cAMP response element (CRE) [83, 84]  
 
LNCaP cells were transiently transfected with control and CRE-luc reporter, 
respectively, and treated with vehicle, or the MRP4 specific inhibitor MK571 or the  
β2AR agonist isoproteronol, or a combination of the ß2AR agonist and MRP4 inhibitor, 
respectively (Fig 3.4). When vehicle treatmentwas compared with the MRP4 inhibitor 
treatment, there was a small but not significant increase in cAMP signaling. Treatment 
with the β2AR agonist isoproteronol alone significantly increased cAMP signaling, and 
co-treatment with the MRP4 inhibitor further increased cAMP signaling. This 
combination also showed the highest increase in CRE-luc levels. These results confirm 
the functional association between MRP4 and ß2AR. 
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Figure 3.4. Activation of ß2AR along with inhibition of MRP4 modifies cAMP 
signaling (CRE-Luc activity).  
 
LNCaP cells were cotransfected with control-MetLuc2 reporter and pSEAP2 (secreted 
alkaline phosphate) control vector or CRE-MetLuc2 and SEAP2 control vector. Cells 
were incubated for 24 hrs after treating with vehicle (0.1% DMSO), MK571 (25 µM), 
Isoproteronol (ISO 250 nM), ISO( 250 nM) + MK571, ISO (500nM), and ISO  
(500nM) + MK571, respectively. Each point represents the mean ± S.E.M. of normalized 
luciferase activities performed in triplicates. ** p < 0.05 compared with DMSO treated 
cells. *** p < 0.009 compared with DMSO treated cells. RLU, relative luciferase units. 
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CHAPTER 4.    DISCUSSION 
 
 
Summary of Conclusions 
 
 MRP4 plays an essential role in regulation of intracellular cAMP levels. This 
regulation parallels the role of phosphodiesterases, which also regulate cAMP levels 
through hydrolysis of cAMP. There have been a number of studies which showed that 
MRP4 regulates cAMP levels in different cell types, but only one study has shown that 
this regulation is possible due to physical and functional association of MRP4 with 
another ABC transporter, CFTR, through its PDZ interacting motif. CFTR is a major 
regulator of fluid homeostasis, and changes in CFTR function could lead to a disturbance 
of fluid homeostasis resulting in diseases like cystic fibrosis, secretary diarrhea or 
inflammatory bowel syndrome. MRP4 is an efflux transporter of cAMP, and CFTR is a 
Clchannel whose function depends on the cAMP levels. If cAMP levels are low, this 
condition may lead to inflammatory bowel syndrome, and when cAMP levels are high, 
this condition may lead to secretary diarrhea. MRP4 regulates localized cAMP levels and 
aids in maintaining fluid homeostasis, along with CFTR. This regulation and association 
is possible because both CFTR and MRP4 bind to a scaffolding protein, PDZK1, through 
their PDZ interacting motifs. PDZK1 plays a role in holding the macromolecular 
complex of CFTR and MRP4, leading to the functional association of MRP4 and CFTR 
[36]. In another study, it has been observed that interaction of MRP4 through its PDZ 
interacting motif with a scaffolding protein, NHERF1, may play a role in MRP4 apical 
localization in polarized cells [47]. 
 
In this study, we found that MRP4, through its PDZ interacting motif, interacts 
with several other scaffolding proteins, along with PDZK1 [15] and NHERF1 [47]. We 
also observed that there is a functional and physical association of MRP4 with β2AR. 
This interaction is possible because both MRP4 and β2AR bind to scaffolding proteins 
through their PDZ interacting motifs. From our results, it is possible that the scaffolding 
protein that holds this macromolecular complex is MAGI3. Further studies have to be 
carried out to confirm whether MAGI3 is the only scaffolding protein that holds this 
complex or there are any other proteins which may carry out the same function when 
MAGI3 is knocked down. We think that the scaffolding protein could be MAGI3 because 
MRP4, β2AR and MAGI3 are co-expressed in LNcAP cells, and co-immunoprecipitation 
studies showed a physical association between MRP4 and β2AR and a weak interaction 
with MAGI3. None of these interactions was changed by treatment with the ß2AR 
agonist isoproteronol. Finally, we also observed a functional association between MRP4 
and β2AR. We showed that inhibition of MRP4 could modify ß2AR-induced cAMP 
signaling in LNCaP cells. Nevertheless, it remains possible that other scaffolding 
proteins, such as NHERF1 and PDZK1 (whose proteins we detected in LNCaP cells), 
could also serve as scaffolds for MRP4 and ß2AR in these cells, and this possibility 
remains to be tested  
 
It remains to be determined whether scaffolding proteins facilitate MRP4’s 
interaction with any other receptors or proteins or modulate MRP4 efflux of cAMP. In rat 
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smooth muscle cells, it has been observed that MRP4 regulates intracellular cAMP levels. 
Inhibition of MRP4 leads to increase in intracellular cAMP, thus leading to an anti-
proliferative effect on rat smooth muscle cells. In these cells, MRP4 negatively regulates 
the cAMP dependent signal transduction pathways [85]. This anti proliferative effect by 
inhibition and knockdown of MRP4 has been observed in human leukemic cell lines as 
well. This effect is due to the increase in intracellular cAMP levels. In human leukemic 
cells, MRP4 controls intracellular cAMP levels, leading to increase in cell proliferation 
and preventing differentiation and maturation [86]. It also has been shown that MRP4 
plays a role in retinal angiogenesis. When human retinal endothelial cells are treated with 
increasing concentration of VEGF, there is a decreased expression of MRP4. Knock 
down of MRP4 in hRECs has shown suppression of apoptosis, increase in migration of 
cells and formation cell aggregates─all of which may be due to the increase in 
intracellular cAMP levels [87]. Recently, it has been shown that MRP4 regulates cAMP 
levels in pulmonary arterial smooth muscle cells. In patients with pulmonary arterial 
hypertension, MRP4 expression has been observed to be increased. Inhibition of MRP4 
leads to decrease in the proliferation and migration of pulmonary arterial endothelial cells 
of mice [88]. All these observations show that MRP4 is a major regulator of intracellular 
cAMP levels. It would be interesting to see whether this regulation involves the role of 
PDZ interacting motif. Exploring this question may lead to finding other interacting 
partners of MRP4 and scaffolding proteins that may be responsible for regulating cAMP 
along with MRP4. 
 
MAGI3 is a scaffolding protein that binds to GPCRs like LPA2 receptor and 
negatively regulates LPA2 invasion and cell migration in colon cancer cell line. NHERF2 
also interacts with LPA2 in the same cells and has an opposite effect on invasion and 
migration compared to that of MAGI3. This differential regulation is possible because 
MAGI3 couples LPA2 with Gαq and Gα12, while NHERF2 couples LPA2 only with Gαq. 
Both MAGI3 and NHERF2 compete for binding to LPA2 receptor,. It has been observed 
that knock down of MAGI3 leads to increased association of NHERF2 to LPA2.LPA2 
expression is higher in prostate cancer [89]. We hypothesized that MAGI3 may also 
present in prostate cancer cells and have shown evidence to support this hypothesis in our 
results. MAGI3 also binds to both β1 and β2AR [31, 77]. LNCaP cells show higher 
expression of β2AR [2, 90]. Even MRP4 is highly expressed in prostate cancer [1, 11]. 
There may be a possibility that knock down of MAGI3 in LNCaP cells may lead to 
association of other PDZ proteins with MRP4 and β2AR. 
 
From the previous studies and our results, we propose a model depicting 
functional and physical association between MRP4 and β2AR, probably through a PDZ 
scaffolding protein, MAGI3 (Fig 4.1). When ß2AR is activated by isoproterenol, it 
interacts with the Gs group of G proteins, stimulating adenylyl cyclase and subsequently 
increasing cAMP levels, leading to activation of PKC. This probably regulates 
downstream cAMP target gene expression. As ß2AR and MRP4 are in a macromolecular 
complex, probably through scaffolding protein MAGI3, these increased levels of cAMP 
due to ß2AR activation are regulated by efflux of cAMP through the efflux transporter 
MRP4. The MRP4/ß2 AR/PDZ protein complex may aid in maintaining homeostasis of 
cAMP levels in cells along with PDE activity. 
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Figure 4.1. Schematic representation of physical and functional association of 
MRP4 with ß2AR through a scaffolding protein, MAGI3, in prostate cancer cell 
line.  
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In conclusion, MRP4 can bind to several scaffolding proteins through its PDZ 
interacting motif. Through this binding, MRP4 can interact with other transporters, 
receptors or ion channels, etc. and may have an effect on the transport of the substrates or 
downstream signaling pathways. In our study, we showed that MRP4 functionally and 
physically associates with β2AR in LNCaP cells. This association may regulate cAMP 
levels, subsequently regulating the downstream gene expression, which is dependent on 
cAMP signaling in LNCaP cells. This association of MRP4 and β2AR may be due to 
their binding to the scaffolding protein MAGI3. 
 
 
Future Studies 
 
 We would like to see the effect on the macromolecular complex of MRP4, β2AR 
and MAGI3 when MAGI3 is knocked down using ShRNA MAGI3 Lentivirus particles. 
We hypothesize that there would be a break down in the physical and functional 
association of MRP4 and β2AR. It would be also interesting to see if there were changes 
in intracellular and extracellular cAMP levels using cAMP assays, along with and 
without knock down of MAGI3.  However, it also remains to be tested whether other 
PDZ proteins that interacted with MRP4 C7 peptide (PDZK1 and NHERF1) and that are 
expressed in LNCaP cells serve as a scaffold for MRP4 and β2AR and affect cAMP 
signaling. It would also be interesting to use confocal microscopy to see the localization 
of all three proteins:,MRP4, β2AR and MAGI3, in LNCaP cells.  
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